The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...

The federal government is suing three big pharmacy benefit managers (PBMs) over a system of drug rebates that regulators say ...

The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.

The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...

FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.

Bloomberg Washington Correspondents Joe Mathieu and Kailey Leinz deliver insight and analysis on the latest headlines from ...

FTC's action today is likely only the tip of the iceberg of necessary reforms to end PBMs' harmful business practices that have directly led to the lights going out for thousands of independent ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Welcome to The Hill’s Business & Economy newsletter{beacon} Business & Economy Business & Economy   The Big Story Would Trump ...

Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...

Parts of Europe have begun dealing with the aftermath of devastating flooding that left dozens dead and hundreds evacuated.